NextCell Pharma publish Interim Report 1 2024/2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 – November 30, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

First Quarter (2024-09-01 to 2024-11-30)

• Operating income amounted to 2,864 (4,695) TSEK, of which Cellaviva contributed 2,828 (4,246) TSEK.
• Net sales amounted to 2,828 (4,246) TSEK.
• Profit/loss after financial items amounted to -8,042 (-9,796) TSEK.
• Earnings per share* were -0.11 (-0.28) SEK.
• Cash and cash equivalents amounted to 34,123 (40,428) TSEK.
• Equity ratio** amounted to 86 (81) percent.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the first quarter of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 30 November 2024: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the first quarter

• At the beginning of September, the Company presented new clinical long-term data at the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting. The results demonstrate the long-term safety and effi­cacy of the treatment in preserving endogenous insulin production, along with additional health benefits for patients with type 1 diabetes (T1D), such as lower BMI and blood pressure.
• At the end of September, the Company announced that the first four children in the 7–11 age group had been treated in the latest phase of the ProTrans-Young study, with an additional four children screened and expected to begin treatment shortly. These developments mark a significant milestone in the study, which is progressing faster than anticipated.
• In early October, the Company announced that Pro­Trans was highlighted as a promising treatment for type 1 diabetes in Dagens Medicin.
• In early November, NextCell Pharma participated in BIO-Europe 2024, one of Europe’s most important partnering conferences in biotechnology and pharma­ceutical development, which was attended by Sweden's Minister for Energy and Enterprise and Deputy Prime Minister, Ebba Busch.
• At the end of November, QVance, a subsidiary of Next­Cell Pharma, announced two significant partnerships with bioMérieux Sweden and Royal International.
• In late November, the Company announced that Eva Sjökvist Saers was elected as a new board member at the Annual General Meeting.

Significant events after the reporting period

• In December, NextCell reported new results from the ProTrans-Repeat study. "The results from the ProTrans-Repeat study are very encouraging and show that repeated treatment can preserve and even improve insulin production over six years. This strengthens ProTrans' potential as a safe and effective treatment for modifying the progression of type 1 diabetes," comment­ed Mathias Svahn, CEO.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on
30th January 2025, 08.30 CET.